Insight into hepatitis B prevalence and risk factors among Vietnamese Americans: a cross-sectional analysis of data from a community-based screening program

Alice W Lee, Wura Jacobs, Elena Chan, Becky Nguyen, Dung N Hua, John N Ho, Priscilla Yuen, Thai Van Nguyen

ABSTRACT

Objectives The aims of our study were to describe current hepatitis B prevalence among Vietnamese Americans and to examine predictors of hepatitis B risk in this specific ethnic community.

Design Cross-sectional analysis of data from a community-based screening program.

Setting This analysis was based on hepatitis screening community events in Southern California.

Participants 2508 Vietnamese Americans in Southern California.

Outcome measures Serological tests for hepatitis B surface antigen, hepatitis B surface antibody, and total hepatitis B core antibody were used to classify participants as one of four hepatitis B infection statuses: currently infected, previously infected, susceptible, or immune due to a previous hepatitis B vaccination.

Results Across 2508 participants, 9.0% were currently infected with hepatitis B and 17.7% were at risk for hepatitis B. Females and those reporting a previous hepatitis B vaccination were at significant decreased risk of hepatitis B (OR=0.48, 95% CI 0.33 to 0.69 and OR=0.53, 95% CI 0.31 to 0.93, respectively) whereas those born outside of the USA and with a family history of infected family members, could help in addressing the disease’s burden in this high-prevalence population.

Introduction Hepatitis B is an important public health issue affecting ~257 million people worldwide. It is associated with substantial increased risk of severe liver diseases including liver cancer, which is the fifth and seventh leading cause of cancer death among males and females, respectively, and the fastest growing cause of cancer death in the USA. Although the USA is considered a low-prevalence region for hepatitis B, the number of infected people is expected to grow due to immigration from endemic regions, particularly in Asia. Asian Americans were the fastest growing racial group in the USA over the last decade. They also have the highest rate of hepatitis B, accounting for >50% of all cases in the USA. However, Asian Americans are often underrepresented in population-based hepatitis B studies and hence aggregated with other racial groups. They also constitute a heterogeneous population, yet most studies evaluate Asian Americans as a single group despite known ethnic-specific variation in hepatitis B’s burden.

Vietnamese Americans have one of the highest prevalences of hepatitis B, ranging from 7% to 14%; they also have high incidence and mortality rates of liver cancer.
In a recent study by Pham et al., incidence of liver cancer among Vietnamese American males was eight times higher than non-Hispanic white males and more than twice that of males of other Asian ancestries. The study also observed little change in liver cancer incidence among Vietnamese American males and significant increasing rates among Vietnamese American females over the last three decades. Since hepatitis B is an underlying cause of liver cancer and Vietnamese Americans are the second fastest growing Asian ethnic group in the USA, there is a critical need to better understand hepatitis B and its risk factors in this subpopulation.

Our study addresses this important area of research by examining hepatitis B specifically in Vietnamese Americans in Southern California, which is home to >300,000 Vietnamese Americans, the highest number of Vietnamese Americans in the USA. Only one study to our knowledge has examined hepatitis B in Vietnamese Americans in this geographic region; it leveraged data from the Vietnamese American Cancer Foundation (VACF), a non-profit organisation located in Fountain Valley, California, from 10 years ago. Here we provide an updated evaluation of hepatitis B prevalence and risk factors using more recent comprehensive serological and questionnaire data from VACF that includes over 2500 Vietnamese Americans. This constitutes one of the largest analyses of hepatitis B in the Vietnamese American community to date.

METHODS

Study population

This analysis was based on data collected from a series of free hepatitis screening community events from February 2011 to November 2017 in two Southern California counties, Orange and Los Angeles, which are home to the largest population of Vietnamese Americans in California and in the USA. These events were organized by the VACF (http://www.vacf.org/), whose mission is to educate and increase awareness of hepatitis and cancers among the Vietnamese community. Their main hepatitis screening events were held twice each year at Orange Coast Memorial Care Medical Center in Fountain Valley, California and advertised in Vietnamese radio and television programs and newspapers as well as through community referral; however, VACF also provided hepatitis screening services at various community health fairs and events.

Because some individuals were likely to have participated in multiple screening events, we only included those who participated in one event. We attempted to avoid duplicate entries by excluding those of the same sex and date of birth since VACF did not keep track of those who received multiple screenings from them. This exclusion resulted in 3264 unique participants. While all who attended the events and desired testing were screened, those who did not report a Southern Californian residence (N=89) or a Vietnamese ethnicity (N=599) were excluded. In addition, we only included those who had confirmed serological testing results for the hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and total hepatitis B core antibody (anti-HBc), leaving us with a final population of 2508 participants; all three serological tests are needed to properly differentiate those truly at risk of hepatitis B from those previously infected or immune via vaccination.

Data ascertainment

All participants receiving VACF screening services were given a self-administered questionnaire in Vietnamese or English by trained staff. The questionnaire included questions regarding participants’ demographics, whether family members have had hepatitis, their hepatitis B vaccination status, and knowledge of their own hepatitis infection status as well as the infection statuses of household members. Written consent was obtained at this time. Participants’ blood was then drawn by trained phlebotomists and later tested for HBsAg, anti-HBs, and anti-HBc by various commercial laboratories in the Orange County region that partner with VACF; the majority of testing was done using Advia Centaur chemiluminescence immunoassay for determining hepatitis serology.

For VACF’s biannual screening events, participants attended a 30-minute lecture on hepatitis B by a physician specializing in liver diseases only after completion of the questionnaire to minimize any bias in their responses and prior to their blood draw. Because the primary language for most screening participants was Vietnamese, the lecture was delivered in Vietnamese; however, lecture slides were presented in English as well. When the screening results were ready to be disseminated (typically within a month after each biannual screening event), VACF organized follow-up events in which they invited a physician to explain the results to the participants, answer any questions as well as discuss next steps. For those unable to attend (~40%–50%), results were mailed with a detailed letter explaining each serological test. Staff also contacted these individuals to link those who tested positive to insurance and/or medical assistance programs for treatment, navigate those at risk to their primary care physicians, community clinics, and/or local pharmacies for vaccinations, and encourage family members and partners to get tested. VACF was not able to organize follow-up events for those who received screening services at community health fairs and events (ie, not VACF’s biannual screening events). However, similar efforts were taken to ensure these individuals received proper follow-up care if needed. Information regarding how many individuals actually received the necessary care was not available due to loss of follow-up.

All data were stored and managed in Community Tech-Knowledge (CTK) Apricot by Social Solutions, a cloud-based client management solution specifically designed for non-profit organizations; CTK Apricot is HIPAA-compliant and data could only be accessed by authorized users via password-protected accounts. The data analyzed
in this report had institutional ethics committee approval from California State University, Fullerton.

**Statistical analysis**

We considered all participants with positive HBsAg and anti-HBc tests to be currently infected with hepatitis B. In addition, those who had an isolated positive anti-HBs test were considered immune due to having been previously vaccinated. Participants who had an isolated positive anti-HBc test or positive anti-HBs and anti-HBc tests were considered as having a previous hepatitis B infection. Lastly, participants who screened negative for all three tests were considered at risk or susceptible to hepatitis B.

Descriptive statistics in percentages were used to characterize the participants with regard to demographics, including age (<40, 40–49, 50–59, 60–69, 70+ years), gender (male/female), annual household income (<US$10 000, US$10 001–US$30 000, US$30 001+), education (less than high school, high school graduate, some college or technical/vocational training, college graduate), marital status (single/married), health insurance status (yes/no) and US birth status (US born/non-US born) as well as relevant hepatitis B information, including family history of hepatitis B (yes/no) and personal history of hepatitis B vaccination (yes/no). A χ² test or Fisher’s exact test (when one or more cells had an expected frequency of five or less) was used to determine whether factors differed across the four hepatitis B statuses (previous infection, immunity from vaccination, currently infected, susceptible). This analytic approach was also used to identify factors associated with risk of hepatitis B (ie, comparing those currently infected to those susceptible). Characteristics found to be associated with risk of hepatitis B were at a p value of ≤0.10 were fit into a multivariate logistic regression model to quantify each factor’s effect on risk of hepatitis B using an odds ratio (OR) and a 95% confidence interval (CI).17 Missing categories were created for all variables and modelled where appropriate. To ensure our selection of significant factors in the fully adjusted model was not driven by differences in the missing categories, sensitivity analyses were conducted excluding the missing. Because the overall findings did not change with and without the missing categories, the results with the missing categories are presented.

All tests of statistical significance were two-sided. The analyses were performed using SAS 9.4 Software. Statistical significance was considered at a p value of ≤0.05.

**Patient and public involvement**

The VACF organized hepatitis screening community events in Orange County, California and Los Angeles County, California every year that were free and open to the public. Participants at these screening events completed a questionnaire and had their blood drawn, which was tested for hepatitis B serology. No specific patient population was included.

**RESULTS**

Among the 2508 participants, 9.0% were currently infected with hepatitis B (N=225) and 17.7% were at risk or susceptible to hepatitis B (N=443). In addition, close to 46% had been previously infected (N=1151) and ~27% were immune due to having received a hepatitis B vaccination (N=689) (table 1).

The majority of participants were female (55.5%), 50 years of age or older (59.0%) and married (64.2%) with no more than a high school education or equivalent (53.1%) and living in a household with an annual income of <US$30 000 (64.7%); almost all participants were born outside of the USA (96.2%) (table 2). When characteristics were examined across the four hepatitis B statuses, significant differences in gender (p=0.02), age (p<0.0001), education (p=0.004), marital status (p<0.0001), US birth status (p<0.0001), family history of hepatitis B (p<0.0001), and personal history of hepatitis B vaccination (p<0.0001) were observed (table 2).

Because gender, age, income, family history of hepatitis B, personal history of hepatitis B vaccination and US birth status were statistically significantly associated with hepatitis B risk when comparing only those susceptible to those currently infected (table 2), we jointly modelled those factors with year of screening and found females to be at a 52% reduced risk of hepatitis B relative to males (OR=0.48, 95% CI 0.33 to 0.69; table 3). In addition, those who reported a previous hepatitis B vaccination were at a 47% reduced risk in comparison to those who did not (OR=0.53, 95% CI 0.31 to 0.93; table 3). However, those born outside of the USA as well as those with a family history of hepatitis B were at substantial increased risk of hepatitis B.

| Table 1 Percentage of screening participants by hepatitis B status |
|---------------------------------------------------------------|
| **Serological results** | **Interpretation** | **No. of participants** | **Percent of participants** |
|------------------------|--------------------|-------------------------|---------------------------|
| HBsAg–, anti-HBs+/-, anti-HBc+ | Previous infection | 1151 | 45.9 |
| HBsAg–, anti-HBs+, anti-HBc– | Immunity from vaccination | 689 | 27.5 |
| HBsAg–, anti-HBs–, anti-HBc– | Susceptible | 443 | 17.7 |
| HBsAg+, anti-HBs+/-, anti-HBc+ | Currently infected | 225 | 9.0 |

*p=Does not total 100% due to rounding.
HBsAg, hepatitis B surface antigen; anti-HBc, total hepatitis B core antibody; anti-HBs, hepatitis B surface antibody.
### Table 2  Characteristics of screening participants by hepatitis B status

| Characteristic               | Previous Infection N (% previous infection)§ | Immunity from vaccination N (% vaccinated)§ | Susceptible N (% susceptible)§ | Currently infected N (% infected)§ | Total* | P value† | P value‡ |
|-----------------------------|----------------------------------------------|---------------------------------------------|--------------------------------|-----------------------------------|--------|---------|---------|
| **Gender**                  |                                              |                                              |                                |                                   |        |         |         |
| Male                        | 540 (46.9)                                  | 276 (40.1)                                  | 176 (39.7)                     | 116 (51.6)                        | 1108   | 0.02    | 0.006   |
| Female                      | 609 (52.9)                                  | 408 (59.2)                                  | 265 (59.8)                     | 108 (48.4)                        | 1390   |         |         |
| Missing                     | 2 (0.2)                                     | 5 (0.7)                                     | 2 (0.5)                        | 0 (0.0)                           | 9      |         |         |
| **Age (years)**             |                                              |                                              |                                |                                   |        | <0.0001 | 0.09    |
| <40                         | 103 (8.9)                                   | 208 (30.2)                                  | 125 (28.2)                     | 45 (20.0)                         | 481    |         |         |
| 40–49                       | 232 (20.2)                                  | 143 (20.8)                                  | 108 (24.4)                     | 62 (27.6)                         | 545    |         |         |
| 50–59                       | 384 (33.4)                                  | 167 (24.2)                                  | 114 (25.7)                     | 68 (30.2)                         | 733    |         |         |
| 60–69                       | 304 (26.4)                                  | 120 (17.4)                                  | 63 (14.2)                      | 39 (17.3)                         | 526    |         |         |
| 70+                         | 126 (11.0)                                  | 50 (7.3)                                    | 33 (7.5)                       | 11 (4.9)                          | 220    |         |         |
| Missing                     | 2 (0.2)                                     | 1 (0.2)                                     | 0 (0.0)                        | 0 (0.0)                           | 3      |         |         |
| **Annual household income** |                                              |                                              |                                |                                   |        | 0.066   | 0.021   |
| ≤US$10 000                  | 363 (31.5)                                  | 208 (30.2)                                  | 137 (20.9)                     | 65 (28.9)                         | 773    |         |         |
| US$10 001 to US$30 000      | 405 (35.2)                                  | 223 (32.4)                                  | 130 (29.4)                     | 91 (40.4)                         | 849    |         |         |
| US$30 001+                  | 185 (16.1)                                  | 115 (16.7)                                  | 92 (20.8)                      | 32 (14.2)                         | 424    |         |         |
| Missing                     | 198 (17.2)                                  | 143 (20.8)                                  | 84 (19.0)                      | 37 (16.4)                         | 462    |         |         |
| **Education**               |                                              |                                              |                                |                                   |        | 0.004   | 0.24    |
| Less than high school       | 260 (22.6)                                  | 104 (15.1)                                  | 87 (19.6)                      | 39 (17.3)                         | 490    |         |         |
| High school graduate        | 394 (34.2)                                  | 225 (32.7)                                  | 136 (30.7)                     | 87 (38.7)                         | 842    |         |         |
| Some college or technical/vocational training | 190 (16.5) | 128 (18.6) | 77 (17.4) | 40 (17.8) | 435 |
| College graduate            | 223 (19.4)                                  | 178 (25.8)                                  | 113 (25.5)                     | 44 (19.6)                         | 558    |         |         |
| Missing                     | 84 (7.3)                                    | 54 (7.8)                                    | 30 (6.8)                       | 15 (6.7)                          | 181    |         |         |
| **Marital status**          |                                              |                                              |                                |                                   |        | <0.0001 | 0.31    |
| Single                      | 290 (25.2)                                  | 264 (38.3)                                  | 147 (33.2)                     | 63 (28.0)                         | 764    |         |         |
| Married                     | 794 (69.0)                                  | 387 (56.2)                                  | 279 (63.0)                     | 150 (66.7)                        | 1610   |         |         |
| Missing                     | 67 (5.8)                                    | 38 (5.5)                                    | 17 (3.8)                       | 12 (5.3)                          | 134    |         |         |
| **Health insurance**        |                                              |                                              |                                |                                   |        | 0.075   | 0.20    |
| No                          | 331 (28.8)                                  | 190 (27.6)                                  | 137 (30.9)                     | 85 (37.8)                         | 743    |         |         |
| Yes                         | 718 (62.4)                                  | 428 (62.1)                                  | 260 (58.7)                     | 118 (52.4)                        | 1524   |         |         |
| Missing                     | 102 (8.9)                                   | 71 (10.3)                                   | 46 (10.4)                      | 22 (9.8)                          | 241    |         |         |
| **Born outside of the USA** |                                              |                                              |                                |                                   |        | <0.0001 | 0.006   |
| No                          | 7 (0.6)                                     | 31 (4.5)                                    | 19 (4.3)                       | 1 (0.4)                           | 58     |         |         |
| Yes                         | 1130 (98.2)                                 | 644 (93.5)                                  | 415 (93.7)                     | 223 (99.1)                        | 2412   |         |         |
| Missing                     | 14 (1.2)                                    | 14 (0.6)                                    | 9 (2.0)                        | 1 (0.4)                           | 38     |         |         |
| **Family history of hepatitis B** |                                              |                                              |                                |                                   |        | 0.0001  | <0.0001 |
| No                          | 707 (61.4)                                  | 395 (57.3)                                  | 281 (63.4)                     | 118 (52.4)                        | 1501   |         |         |
| Yes                         | 116 (10.1)                                  | 69 (10.0)                                   | 37 (8.4)                       | 44 (19.6)                         | 266    |         |         |
| Missing                     | 328 (28.5)                                  | 225 (32.7)                                  | 125 (28.2)                     | 63 (28.0)                         | 741    |         |         |

Continued
Table 2 Continued

| Characteristic                       | Previous Infection N (% previous infection)§ | Immunity from vaccination N (% vaccinated)§ | Susceptible N (% susceptible)§ | Currently infected N (% infected)§ | Total* | P value† | P value‡ |
|--------------------------------------|----------------------------------------------|----------------------------------------------|--------------------------------|-----------------------------------|--------|----------|----------|
| Previous hepatitis B vaccination     |                                              |                                              |                                |                                   |        |          |          |
| No                                   | 662 (57.5)                                   | 263 (38.2)                                   | 245 (55.4)                     | 150 (66.7)                        | 1320   | <0.0001  | 0.017    |
| Yes                                  | 203 (17.6)                                   | 225 (32.7)                                   | 71 (16.0)                      | 25 (11.1)                         | 524    |           |          |
| Missing                              | 286 (24.9)                                   | 201 (29.2)                                   | 127 (28.7)                     | 50 (22.2)                         | 664    |           |          |
| Total                                | 1151                                         | 689                                          | 443                            | 225                               | 2508   |          |          |

*Number of participants by each characteristic.
†χ² p value comparing all four hepatitis B statuses.
‡χ² p value comparing only those susceptible to hepatitis B to those currently infected with hepatitis B.
§May not total 100% due to rounding.

Table 3 ORs and 95% CIs for the association between screening participant characteristics and risk of hepatitis B

| Characteristic                           | OR* | 95% CI         | P value |
|------------------------------------------|-----|----------------|---------|
| Gender                                   |     |                |         |
| Male                                     | 1.00| –              | –       |
| Female                                   | 0.48| 0.33 to 0.69   | <0.0001 |
| Age (years)                              |     |                |         |
| <40                                      | 1.00| –              | –       |
| 40–49                                    | 1.40| 0.83 to 2.36   | 0.20    |
| 50–59                                    | 1.58| 0.95 to 2.62   | 0.078   |
| 60–69                                    | 1.54| 0.85 to 2.79   | 0.15    |
| 70+                                      | 0.76| 0.32 to 1.77   | 0.52    |
| Annual household income                  |     |                |         |
| ≤US$10,000                               | 1.00| –              | –       |
| US$10,001 to US$30,000                   | 1.32| 0.86 to 2.03   | 0.35    |
| US$30,001+                               | 0.56| 0.32 to 0.99   | 0.046   |
| Born outside of the USA                  |     |                |         |
| No                                       | 1.00| –              | –       |
| Yes                                      | 13.36| 1.62 to 110.05 | 0.016   |
| Family history of hepatitis B            |     |                |         |
| No                                       | 1.00| –              | –       |
| Yes                                      | 4.68| 2.66 to 8.22   | <0.0001 |
| Previous hepatitis B vaccination         |     |                |         |
| No                                       | 1.00| –              | –       |
| Yes                                      | 0.53| 0.31 to 0.93   | 0.023   |

*Adjusted for all other characteristics as well as year of screening.

(OR=13.36, 95% CI 1.62 to 110.05 and OR=4.68, 95% CI 2.66 to 8.22, respectively; table 3). We conducted a subset analysis among those born outside of the USA to examine whether year of entry into the USA would differentially affect risk; however, no significant association was found (data not shown). Lastly, there appeared to be increased risk after age 40 (OR=1.40, 1.58, 1.54 for 40–49, 50–59, 60–69 years, respectively) until age 70 (OR=0.76) although none of the effect estimates were statistically significant (table 3).

DISCUSSION

Although the literature recognizes Asian Americans as having the highest rate of hepatitis B in the USA, the overall Asian population is diverse with variations in disease burden by ethnicity. For this reason, our report focuses specifically on Vietnamese Americans who have one of the highest prevalences of hepatitis B. Using data from community screening events from 2011 to 2017, 9.0% of participants were currently infected with hepatitis B; this is similar to the 8.8% prevalence determined by Nguyen et al’s study of VACF data spanning 2008–2010, indicating little change in disease prevalence for this community. Nguyen et al also observed 15.4% of their participants were at risk of hepatitis B, 53.8% had a previous infection, and 21.9% were immune from vaccination; this is in comparison to our percentages of 17.7%, 45.9%, and 27.5%, respectively. Given efforts to improve understanding of hepatitis B among the Vietnamese American community, it is not surprising that our updated evaluation shows a greater proportion with immunity from vaccination and a lower proportion with natural immunity via a previous infection. However, we did observe a higher percentage of susceptible participants, which may be a result of increased awareness prompting those still at risk to undergo screening. This higher percentage could also reflect a growth in the number of at-risk Vietnamese Americans in the Southern California region, highlighting the need for continued hepatitis B public health efforts.
Not surprisingly, most participants whose serology indicated immunity from vaccination were those who reported having been previously vaccinated. However, among those who reported a previous vaccination, only 42.9% possessed protective antibodies with 13.6% still susceptible to hepatitis B and 4.8% currently infected with hepatitis B. This discrepancy between self-reported vaccination status and confirmed serology is an important issue and could be due to several reasons. First, participants may have inaccurately reported their vaccination status because they confused a vaccine for another disease with a vaccine for hepatitis B. The contrary may also be true; our data showed close to 20% of those who reported not having been previously vaccinated possessing protective antibodies that indicate previous immunization. Second, because the hepatitis B vaccine is given as a series of shots over a 6-month time period, some participants may not have received all necessary shots and hence were not immunized, but thought they were. These reasons highlight the need for improved health education and hepatitis B vaccination knowledge in the Vietnamese American community. Another explanation for why some participants who reported being vaccinated were currently infected may be due to the fact that they were already infected at the time of their vaccination. It is currently not standard clinical practice to test for hepatitis B prior to administering the vaccine, but this may be worthwhile to do particularly for high-risk individuals.18

Our study found those born outside of the USA to be over 13 times as likely to be infected with hepatitis B compared with those born in the USA, a finding supported by another screening study by Kallman et al.19 Given that these individuals are likely immigrants from Vietnam, they may lack knowledge regarding hepatitis B and hence are unaware of their infection status. Unlike the USA where there is a multipronged strategy for hepatitis B prevention (eg, antenatal screenings, hepatitis B immune globulin at birth for babies born to mothers who are HBsAg-positive, two-dose hepatitis B vaccine for adults, education and awareness of accessible resources for reducing transmission), migrants from Vietnam where there is a heavy reliance on infant vaccination as the main prevention strategy could be at higher risk due to lack of awareness of disease transmission and prevention strategies.20 There could also be a lack of health literacy or access to care due to financial, linguistic, and cultural barriers (eg, stigma, feelings of shame and guilt), which have been documented as contributing factors to health disparities among Vietnamese Americans and Asian American immigrants generally.21–24 More culturally tailored public health programs and interventions that aim to increase hepatitis B awareness and knowledge, particularly among Vietnamese Americans born outside of the USA, are needed.

We identified family history as a significant predictor of hepatitis B risk, which is in line with other screening studies conducted in Vietnamese Americans and Asian Americans.12 18 19 The substantial increased risk among those with a family history is not surprising given that hepatitis B is often transmitted from an infected mother to her baby during birth or through direct contact with blood, semen, or other bodily fluids from an infected person. We also identified gender as a significant predictor with females having a lower risk of hepatitis B than males, which may be a result of biological factors and gender-specific health behaviours and perceptions. Biologically, the observed sex disparity could be due to differences in immune responses which are shaped by sex steroid hormones (eg, androgens, estrogens) that have been shown to influence the function of immune cells and interact with the complex clinical course of hepatitis B.25 26 Behaviorally, females are generally more health conscious and hence may have higher levels of hepatitis B awareness and knowledge as well as greater use of hepatitis B-related prevention services.27 28 Males also tend to possess certain lifestyle factors that promote the adoption of more traditional masculine perspectives that underplay the importance of health-protective behaviours.29 30 For example, a Vietnamese American male who constructs masculinity as self-reliance or putting work ahead of all other responsibilities may not make time for self-care or seek routine health services, indicating a need to improve health education and outreach for males.

The strengths of our analysis include its large sample size as well as our primary focus on Vietnamese Americans, a community disproportionately burdened by hepatitis B. With the growing literature highlighting the need to disaggregate Asian Americans in research due to the diverse cultures, languages, and sociodemographic factors that characterize each Asian subgroup, it is important that ethnic-specific data are used so more effective public health strategies can be developed.31 Our study also used serological tests for HBsAg, anti-HBc, and anti-HBs to accurately classify each participant’s hepatitis B status. Many screening fairs have relied solely on HBsAg testing despite the need for anti-HBs and anti-HBc tests to properly identify those truly at risk. We recognize that our findings may not necessarily be generalizable to the entire Vietnamese American population given that attendees of health fairs that offer free services are often foreign-born and from low-income backgrounds. This is indeed true in our analysis since the majority of participants were foreign-born with an annual household income of <US$30 000 in comparison to only 64% of Vietnamese in the USA who are foreign-born with a median annual household income of US$58 700 according to data from the 2013-2015 American Community Survey (ACS).15 However, there is some comparability with regard to education and marital status when the ACS data are restricted to only those foreign-born (eg, percent who have a high school education or less: 53% in our data vs 52% in the ACS, percent who are married: 61% in our data vs 64% in the ACS).15 In addition, Southern California has the highest concentration of Vietnamese Americans in the USA, making it the ideal region to study hepatitis B for this ethnicity.
Other limitations of our analysis include the lack of information on other factors that may affect hepatitis B risk as well as missing participant data for certain characteristics. These are often issues with questionnaires administered at screening fairs due to time constraints. We did conduct sensitivity analyses with and without the missing data and the overall results did not change. Lastly, our questionnaire data were based on self-report, which may result in misclassification as we noted for participants’ hepatitis B vaccination status. However, there is little reason to believe that the misclassification would occur more or less often for those of a certain hepatitis B status, hence any bias would only be towards the null.

Overall, our study provides an updated evaluation on hepatitis B prevalence in the Vietnamese American community and identifies certain subgroups within it, particularly those born outside of the USA and those with a hepatitis B family history, who may be at increased risk and require targeted interventions. In addition, we observed important discrepancies between self-reported hepatitis B vaccination status and confirmed serological results, which highlight the need to improve hepatitis B vaccination knowledge among Vietnamese Americans and their health providers. Our comprehensive serological testing makes this a unique effort with findings that can inform strategies to address hepatitis B’s burden in the Vietnamese American community.

Contributors AWL, WJ, BN, and TVN contributed to the conception and design of the study. BN, DNH, JHJN, and TVN contributed to the study’s data collection. AL, WJ, EC, and PY contributed to statistical analysis and interpretation of the data. AL, WJ, and EC drafted the manuscript. All authors reviewed and approved the final version of the manuscript.

Funding The Vietnamese American Cancer Foundation is a non-profit organisation that is supported by generous donations and fundraising from community members and local organisations.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval All data analysed in this report had institutional ethics committee approval from California State University, Fullerton (research project number: HSR-17-18-715).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No additional data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES
1. World Health Organization. Hepatitis B. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b [Accessed 26 May 2019].
2. American Cancer Society. Cancer Facts & Figures, 2018. Available: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html [Accessed 30 Sep 2018].
3. Islami F, Miller KD, Siegel RL, et al. Disparities in liver cancer occurrence in the United States by race/ethnicity and state. CA Cancer J Clin 2017;67:273–89.
4. Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis Infection. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington DC: National Academies Press, 2010.
5. Nguyen MH, Keeffe EB. Chronic hepatitis B and hepatitis C in Asian Americans. Rev Gastroenterol Disord 2003;3:125–34.
6. Asian Pacific American Legal Center, Asian American Justice Center. A Community of Contrasts - Asian Americans in the United States, 2011. Available: https://apaclassroom.org/report/community-contrasts-asian-americans-united-states [Accessed 29 Aug 2018].
7. Office of Minority Health. Chronic Hepatitis B in Asian Americans, Native Hawaiians and Other Pacific Islanders: Background, 2008. Available: https://minorityhealth.hhs.gov/Default.aspx [Accessed 29 Aug 2018].
8. Kowdle KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012;56:422–33.
9. Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander American (APIA): how can we do better for this special population? Am J Gastroenterol 2008;103:1824–33.
10. McQuillan GM, Coleeman PJ, Kruszon-Moran D, et al. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999;89:14–18.
11. Chang ET, Keggan THM, Gomez SL, et al. The burden of liver cancer in Asians and Pacific Islanders in the Greater San Francisco Bay Area, 1990 through 2004. Cancer 2007;109:2100–8.
12. Ha NB, Trinh HH, Nguyen TT, et al. Prevalence, risk factors, and disease knowledge of chronic hepatitis B infection in Vietnamese Americans in California. J Cancer Educ 2013;28:319–24.
13. Pham C, Fong TL, Zhang J, et al. Striking racial/ethnic disparities in liver cancer incidence rates and temporal trends in California, 1988-2012. J Natl Cancer Inst 2018;110:1259–69.
14. United States Census Bureau. The American Community - Asians, Vietnamese-in-the-us-fact-sheet/ [Accessed 10 Jun 2019].
15. Nguyen K, Van Nguyen T, Shen D, et al. Prevalence and presentation of hepatitis B and C virus (HBV and HCV) infection in Vietnamese Americans via serial community serologic testing. J Immigrant Minority Health 2015;17:13–20.
16. Khali AM, Tran S, Arsalia A, et al. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat 2011;18:70–6.
17. Ranganathan P, Premaratna A, Aggarwal R. Common pitfalls in statistical analysis: logistic regression. Perspect Clin Res 2017;8:148–51.
18. Lin SY, Chang ET, So SK. Why should we routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007;46:1034–40.
19. Kallman JB, Tran S, Arsalia A, et al. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat 2011;18:70–6.
20. Nguyen VT. Hepatitis B infection in Vietnam: current issues and future challenges. Asia Pac J Public Health 2012;24:361–73.
21. Lee S, Martinz G, Ma GX, et al. Barriers to health care access in 13 Asian American communities. Am J Health Behav 2010;34:21–30.
22. Lee H, Kiang P, Watanabe P, et al. Hepatitis B virus infection and immunizations among Asian American college students: infection, exposure, and immunity rates. J Am Coll Health 2013;61:67–74.
23. Choe JH, Taylor VM, Yasui Y, et al. Health care access and sociodemographic factors associated with hepatitis B testing in Vietnamese American men. J Immigrant Minority Health 2006;8:193–201.
24. Davis T, Cheng A, Tran P, et al. Hepatitis B stigma among Vietnamese in Ho Chi Minh City and Chicago. Can J Gastroenterol Hepatol 2016;19:10292.
25. Montella M, D’Arenza G, Crispo A, et al. Role of sex hormones in the development and progression of hepatitis B virus-associated hepatocellular carcinoma. Int J Endocrinol 2015;85430.
26. Ruggeri A, Gagliardi MC, Anticoli S. Sex-Dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses? Front Immunol 2018;9:2302.
27. Taylor VM, Choe JH, Yasui Y, et al. Hepatitis B awareness, testing, and knowledge among Vietnamese American men and women. J Community Health 2005;30:477–90.
28. Taylor VM, Yasui Y, Burke N, et al. Hepatitis B testing among Vietnamese American men. Cancer Detect Prev 2004;28:170–7.
29. Mahalik JR, Burns SM, Syzdek M. Masculinity and perceived normative health behaviors as predictors of men’s health behaviors. Soc Sci Med 2007;64:2201–9.
30. Courtney WH. Constructions of masculinity and their influence on men’s well-being: a theory of gender and health. Soc Sci Med 2000;50:1385–401.
31. Hoenig ND, Palaniappan LP. Problems with the collection and interpretation of Asian-American health data: omission, aggregation, and extrapolation. Ann Epidemiol 2012;22:397–405.